ArticleJournal of immunology (Baltimore, Md. : 1950)2003
Mechanisms of ganglioside inhibition of APC function.
Article in Journal of immunology (Baltimore, Md. : 1950), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 79 citations in OpenAlex.
- Synthesis, function, and therapeutic potential of glycosphingolipids.Frontiers in immunology · 2025Review
- Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial.Nature communications · 2024Article
- Limited impact of cancer-derived gangliosides on anti-tumor immunity in colorectal cancer.Glycobiology · 2024Article
- Review
- Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment.Cancer metastasis reviews · 2023Review
- Review
- The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides.Frontiers in oncology · 2023Review
- The biological role and immunotherapy of gangliosides and GD3 synthase in cancers.Frontiers in cell and developmental biology · 2023Review
- Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity.Cancers · 2022Review
- Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome.Journal for immunotherapy of cancer · 2020Article
- The Role of Glycosphingolipids in Immune Cell Functions.Frontiers in immunology · 2019Review
- IFN-γ and tumor gangliosides: Implications for the tumor microenvironment.Cellular immunology · 2018Article
- Lipid glycosylation: a primer for histochemists and cell biologists.Histochemistry and cell biology · 2017Review
- Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells.Oncotarget · 2016Article
- The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression.Frontiers in oncology · 2016Review
- Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Oncoimmunology · 2015Review
- Mesothelioma tumor cells modulate dendritic cell lipid content, phenotype and function.PloS one · 2015Article
- Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents.Frontiers in oncology · 2015Review
- Glycolipid sensing and innate immunity in paracoccidioidomycosis.Mycopathologia · 2014Article
- Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells.Cancer research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Gangliosides shed by tumor cells exert potent inhibitory effects on cellular immune responses. Here we have studied ganglioside inhibition of APC function. When human monocytes were preincubated in 50 micro M highly purified ganglioside G(D1a), pulsed with tetanus toxoid (TT), and washed, the expected Ag-induced proliferative response of autologous normal T cells added to these monocytes was inhibited by 81%. Strikingly, there was also almost complete (92%) and selective inhibition of the up-regulation of the monocyte costimulatory molecule CD80, while I-CAM-1, LFA-3, HLA-DR, and CD86 expression were unaffected. Purified LPS-stimulated monocytes that had been preincubated in G(D1a) likewise showed inhibition of CD80 up-regulation (59%) as well as down-regulation of CD40 (54%) and impaired release of IL-12 and TNF-alpha (reduced by 59 and 51%). G(D1a)-preincubated human dendritic cells (DC) were also affected. They had reduced constitutive expression of CD40 (33%) and CD80 (61%), but not CD86, and marked inhibition of release of IL-6 (72%), IL-12 (70%), and TNF-alpha (46%). Even when pulsed with TT, these ganglioside-preincubated DC remained deficient in costimulatory molecule expression and cytokine secretion and were unable to induce a normal T cell proliferative response to TT. Finally, significant inhibition of nuclear localization of NF-kappaB proteins in activated DC suggests that disruption of NF-kappaB activation may be one mechanism contributing to ganglioside interference with APC expression of costimulatory molecules and cytokine secretion, which, in turn, may diminish antitumor immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.